Is ursodeoxycholic acid safe to use with emtricitabine/tenofovir (HIV PrEP) and my other medications (metformin and dapagliflozin) without dose adjustments or renal concerns?

Ursodeoxycholic Acid is Safe with Your Current Medications

Ursodeoxycholic acid (UDCA) can be safely used alongside emtricitabine/tenofovir (FTC/TDF) for HIV PrEP, metformin, and dapagliflozin without dose adjustments or significant drug interaction concerns.

No Clinically Significant Drug Interactions

UDCA has minimal systemic absorption and primarily acts locally in the biliary system. Based on the pharmacokinetic profiles:

• Dapagliflozin: Metabolized primarily via UGT1A9 with minor CYP involvement. Dapagliflozin does not inhibit or induce major CYP enzymes and has minimal interaction potential with other drugs 1. UDCA does not affect these pathways.

• Metformin: Renally eliminated unchanged without hepatic metabolism. No interaction expected with UDCA.

• FTC/TDF: Both are renally eliminated with minimal hepatic metabolism 2. UDCA does not affect renal drug transporters or elimination pathways relevant to these antiretrovirals.

Renal Safety Considerations

Your primary concern should focus on the cumulative renal effects of your existing medications, not UDCA:

Tenofovir Disoproxil Fumarate (TDF) Monitoring

• TDF causes a small, nonprogressive decline in creatinine clearance (mean -2.4 ml/min at week 4) that is reversible upon discontinuation 3
• Risk factors for clinically significant decline include age >50 years or baseline CrCl <90 ml/min 4
• Monitor estimated creatinine clearance: at 1 month after PrEP initiation, then quarterly for the first year, then annually 5
• More frequent monitoring (every 3-6 months) is warranted if you have baseline renal impairment or other risk factors 5

Dapagliflozin Considerations

• Dapagliflozin exposure increases by 45-200% in renal impairment, but this does not require dose adjustment in mild-moderate dysfunction 1
• The drug causes increased urinary glucose excretion (~70 grams/day) and urinary volume 1

Combined Effect

• UDCA does not add renal risk to this regimen
• The combination of TDF and dapagliflozin requires standard renal monitoring as outlined above
• Both metformin and emtricitabine require dose adjustment if eGFR falls below certain thresholds, but UDCA does not influence this

Practical Management Algorithm

1. Baseline assessment (if not recently done):

   • Serum creatinine and calculate eGFR/CrCl
   • Hepatitis B surface antigen (required before PrEP) 5

2. Initiate UDCA without dose adjustment of other medications

3. Follow standard PrEP monitoring schedule 5:

   • 1-month visit: HIV testing, creatinine
   • Quarterly: HIV testing, creatinine (if risk factors present)
   • Annually: HIV testing, creatinine (minimum)

4. No additional monitoring required specifically for UDCA interactions

Important Caveats

• If you develop new renal impairment (eGFR <60 ml/min), this would trigger dose adjustments for emtricitabine 2 and potentially metformin, but not due to UDCA
• The reversible nature of TDF-related renal changes means early detection through monitoring prevents progression 3
• UDCA is generally well-tolerated with minimal systemic effects, making it one of the safest additions to complex medication regimens